Title : Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.

Pub. Date : 2021 Jul

PMID : 33860837






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sorafenib resistance may be related to Src-induced cell migration and angiogenesis, which are regulated by cancer stem cell activation and release of vascular endothelial growth factor. Sorafenib vascular endothelial growth factor A Homo sapiens
2 Sorafenib and dasatinib combined treatment suppresses cell migration and angiogenesis by inhibiting the Src/FAK phosphorylation, cell-to-cell contact, cancer stem cell activation, and release of vascular endothelial growth factor. Sorafenib vascular endothelial growth factor A Homo sapiens